Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2021 Jun;10(3):167-180. doi: 10.1159/000516491. Epub 2021 May 25.
Abstract
摘要
相似文献
1
Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update.日本肝细胞癌的监测、诊断及治疗结果：2021年更新
Liver Cancer. 2021 Jun;10(3):167-180. doi: 10.1159/000516491. Epub 2021 May 25.
2
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.《日本肝癌研究组基于JSH共识的肝细胞癌管理临床实践指南：2014年更新》
Liver Cancer. 2014 Oct;3(3-4):458-68. doi: 10.1159/000343875.
3
Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan.肝癌监测中检出的肝癌患者的预后：美国与日本的比较。
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2379-2388.e6. doi: 10.1016/j.cgh.2020.10.033. Epub 2020 Oct 22.
4
Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update.日本肝癌研究学会提出的肝细胞癌监测和诊断算法：2014 年更新版。
Oncology. 2014;87 Suppl 1:7-21. doi: 10.1159/000368141. Epub 2014 Nov 22.
5
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.肝细胞癌临床实践指南：日本肝脏学会2017年（第4版日本肝脏学会肝细胞癌指南）2019年更新版
Hepatol Res. 2019 Oct;49(10):1109-1113. doi: 10.1111/hepr.13411. Epub 2019 Sep 6.
6
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.日本肝细胞癌的监测、诊断及治疗结果：2023年更新
Liver Cancer. 2023 Mar 9;12(2):95-102. doi: 10.1159/000530079. eCollection 2023 Jun.
7
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).循证临床实践指南治疗肝细胞癌：日本肝脏学会 2013 年更新版（第 3 版 JSH-HCC 指南）。
Hepatol Res. 2015 Jan;45(2). doi: 10.1111/hepr.12464.
8
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.日本肝细胞癌的管理：2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
9
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.AGA 临床实践更新：口服直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的相互作用：专家综述。
Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
10
Improved survival of viral hepatocellular carcinoma but not non-viral hepatocellular carcinoma from 2000 to 2020: A multi-centre cohort study of 6007 patients from high-volume academic centres in Japan.2000 年至 2020 年病毒型肝癌生存率提高，但非病毒型肝癌生存率未提高：来自日本大容量学术中心的 6007 例患者的多中心队列研究。
Aliment Pharmacol Ther. 2022 Aug;56(4):694-701. doi: 10.1111/apt.17088. Epub 2022 Jun 16.
引用本文的文献
1
Outcome and Prognosis of Invasive Treatment for Hepatocellular Carcinoma in Very Elderly Patients Over 90 Years Old.90岁以上高龄肝细胞癌患者侵入性治疗的结局与预后
Turk J Gastroenterol. 2025 Jan 13;36(6):381-389. doi: 10.5152/tjg.2025.24163.
2
The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma.一线全身治疗后序贯治疗对不可切除肝细胞癌的影响
J Clin Med. 2024 Apr 29;13(9):2612. doi: 10.3390/jcm13092612.
3
Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.经动脉化疗栓塞联合肝动脉灌注化疗治疗不可切除性大肝癌的疗效与安全性对比研究
J Gastrointest Oncol. 2024 Feb 29;15(1):346-355. doi: 10.21037/jgo-23-821. Epub 2024 Feb 28.
4
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.日本肝细胞癌的当前治疗策略
Liver Cancer. 2023 Oct 3;12(6):497-509. doi: 10.1159/000534304. eCollection 2023 Dec.
5
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era.不同时期序贯治疗晚期肝细胞癌的生存改善情况。
Cancers (Basel). 2023 Nov 6;15(21):5298. doi: 10.3390/cancers15215298.
6
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.日本肝细胞癌的监测、诊断及治疗结果：2023年更新
Liver Cancer. 2023 Mar 9;12(2):95-102. doi: 10.1159/000530079. eCollection 2023 Jun.
7
Management of hepatocellular carcinoma in patients who are 70 years or older.70岁及以上肝细胞癌患者的管理
Surg Open Sci. 2022 Jul 22;10:53-58. doi: 10.1016/j.sopen.2022.07.003. eCollection 2022 Oct.
8
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.根据改良实体瘤疗效评价标准（mRECIST）评估的初始乐伐替尼治疗的客观缓解是乐伐替尼-经动脉化疗栓塞序贯治疗肝细胞癌深度缓解的独立影响因素。
Liver Cancer. 2022 Feb 15;11(4):383-396. doi: 10.1159/000522424. eCollection 2022 Jul.
9
The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan.日本多中心 19 年经验：老年肝细胞癌患者的预后。
Cancer Med. 2023 Jan;12(1):345-357. doi: 10.1002/cam4.4850. Epub 2022 May 24.
10
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.阿替利珠单抗联合贝伐珠单抗治疗老年肝细胞癌患者的安全性和有效性：一项多中心分析。
Cancer Med. 2022 Oct;11(20):3796-3808. doi: 10.1002/cam4.4763. Epub 2022 Apr 19.
本文引用的文献
1
Report of the 18th follow-up survey of primary liver cancer in Japan.日本原发性肝癌第18次随访调查报告。
Hepatol Res. 2010 Nov;40(11):1043-1059. doi: 10.1111/j.1872-034X.2010.00731.x.
2
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.日本肝细胞癌的管理：2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
3
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).肝细胞癌诊疗指南（2019年版）
Liver Cancer. 2020 Dec;9(6):682-720. doi: 10.1159/000509424. Epub 2020 Nov 11.
4
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.老龄化社会中肝细胞癌全身治疗的最新进展：2020年更新
Liver Cancer. 2020 Dec;9(6):640-662. doi: 10.1159/000511001. Epub 2020 Nov 17.
5
Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011).日本第21次全国原发性肝癌随访调查（2010 - 2011年）报告
Hepatol Res. 2021 Apr;51(4):355-405. doi: 10.1111/hepr.13612. Epub 2021 Mar 4.
6
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.肝动脉灌注化疗与索拉非尼治疗晚期肝细胞癌的疗效比较
Liver Cancer. 2020 Sep;9(5):583-595. doi: 10.1159/000508724. Epub 2020 Jul 24.
7
A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development.在肝癌发生高风险人群中，双年度两阶段低剂量肝脏CT与超声用于肝癌监测的比较
Liver Cancer. 2020 Sep;9(5):503-517. doi: 10.1159/000506834. Epub 2020 Aug 6.
8
A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma.钆塞酸二钠增强MRI的新诊断标准可能会提高肝细胞癌的诊断性能。
Liver Cancer. 2020 Aug;9(4):414-425. doi: 10.1159/000505696. Epub 2020 Apr 14.
9
How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT.如何最佳检测符合米兰标准的肝细胞癌患者的门静脉肿瘤血栓形成：钆塞酸二钠增强磁共振成像与对比增强计算机断层扫描的比较
Liver Cancer. 2020 Jun;9(3):293-307. doi: 10.1159/000505191. Epub 2020 Jan 28.
10
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.中期肝细胞癌治疗模式的转变：亚太地区原发性肝癌专家共识声明
Liver Cancer. 2020 Jun;9(3):245-260. doi: 10.1159/000507370. Epub 2020 May 13.
Zotero 插件